Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2025-04-18
Target enrollment:
Participant gender:
Summary
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics
(PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of
PF-07248144 as a single agent and in combination with either fulvestrant or letrozole +
palbociclib.